Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy.
about
Mammalian α arrestins link activated seven transmembrane receptors to Nedd4 family e3 ubiquitin ligases and interact with β arrestinsThe role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision makingIdentification of inherited genetic variations influencing prognosis in early-onset breast cancerEssential gene profiles in breast, pancreatic, and ovarian cancer cells.Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancerFine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancerGenetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapyBromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer.Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survivalGenetic polymorphisms of matrix metalloproteinases and clinical outcomes in colorectal cancer patientsImpact of interleukin-10 gene polymorphisms on survival in patients with colorectal cancerGermline genetic profiling in prostate cancer: latest developments and potential clinical applications.Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer.Human basonuclin 2 up-regulates a cascade set of interferon-stimulated genes with anti-cancerous properties in a lung cancer model.The genetic epidemiology of prostate cancer and its clinical implications.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients.Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancerVEGFA rSNPs, transcriptional factor binding sites and human disease.Vitamin D receptor-binding site variants affect prostate cancer progression.Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.A common regulatory variant in SLC35B4 influences the recurrence and survival of prostate cancer.PSMD7 downregulation induces apoptosis and suppresses tumorigenesis of esophageal squamous cell carcinoma via the mTOR/p70S6K pathway.
P2860
Q24305954-71B7750F-ACD4-431B-BEBD-CA0A5263C0EEQ27025062-3103B2C9-F443-4B28-B737-6AAE8D5E3A5EQ28943279-4ABB17E8-AA45-4A89-AD4A-99EAA59B0A28Q34268870-BD194BFC-313E-4779-93F3-1E65D2234C90Q34566518-8051393F-9BF3-42DA-AA03-691E01A87606Q35163551-2387E825-5E9D-4C9F-A55E-14FBB7A32F40Q36109818-CFA7FC66-EAC2-4461-894B-0489828EE8D9Q36328751-919F1A5A-F713-4608-84AB-5809FA604FAFQ36606039-D648F68B-0080-49F5-9DE9-D5F1D6B844B4Q36953130-D4437647-54F0-449A-8510-2F06DF6B8828Q37147321-914B9574-6A82-4475-89AE-970361D5D7BDQ37474516-8DEF8840-072C-4D5B-A063-C7EEF7298841Q37613206-AFCC9FAF-534E-4661-9EB6-BB78B50286BAQ37628005-E2C8C49B-FB37-48B1-BF0D-B5BC0984F8CDQ38168060-B820FD43-376C-4242-A5A8-A0A67F63EF99Q38184622-232FF6E9-B289-4864-B48A-FC4BB16C17FDQ39032104-DD2285F0-52CC-45E5-9944-2734F3A200E2Q42322498-23EAC6AC-0042-4BE9-BCFE-9158D188F19CQ43622589-DEA9F87B-2981-4FBA-9B57-278E7FFCD19DQ47110997-B8A2F2D2-50C1-4916-8774-322266CD58E9Q52645860-603C3948-931C-4932-873F-DAE93533EB90Q52717553-D6B69119-067F-4308-83B7-F253B8D6742FQ52720455-D5CA7627-3289-4795-8AB7-A6ACB2AA2FF6
P2860
Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Genetic polymorphisms in andro ...... androgen-deprivation therapy.
@en
Genetic polymorphisms in andro ...... androgen-deprivation therapy.
@nl
type
label
Genetic polymorphisms in andro ...... androgen-deprivation therapy.
@en
Genetic polymorphisms in andro ...... androgen-deprivation therapy.
@nl
prefLabel
Genetic polymorphisms in andro ...... androgen-deprivation therapy.
@en
Genetic polymorphisms in andro ...... androgen-deprivation therapy.
@nl
P2093
P2860
P356
P1433
P1476
Genetic polymorphisms in andro ...... g androgen-deprivation therapy
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDR264
P577
2011-06-06T00:00:00Z